TG Therapeutics rises on new data for autoimmune therapy

Shares of biotech firm TG Therapeutics TGTX.O rise 2.7% to $28.51 premarket

 Presented new findings on multiple sclerosis therapy Briumvi for treating a relapsing type of the nerve disorder

Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body

Updates include real‑world data and studies in children and teens

 Most common side effects were infusion reactions and respiratory infections; serious infections seen in 5% of patients

Shares ended marginally lower in 2025